HEMOSTATIC PARAMETERS IN SEPSIS PATIENTS TREATED WITH ANTI-TNF±-MONOCLONAL ANTIBODIES

Authors:
  • PBPeter Boekstegers
    Peter Boekstegers
  • EHErnst Holler
    Ernst Holler
  • KWKarl Werdan
    Karl Werdan
  • SRSrigitte Reinhardt
    Srigitte Reinhardt
  • SFSusanne Fateh-Moghadam
    Susanne Fateh-Moghadam
  • RPRudolf Pihusch
    Rudolf Pihusch
  • MKMartin Kaul
    Martin Kaul
  • TBThomas Beinert
    Thomas Beinert
  • EHErhardt Hiller
    Erhardt Hiller
Publisher website
Google Scholar
Abstract
Tumor necrosis factor-± (TNF±) is a central mediator in the pathogenesis of sepsis. It also interferes with the hemostatic system and exerts a net procoagulant effect. Since TNFa may contribute to thrombotic complications in sepsis patients, we determined markers of thrombin activation, parameters of the fibrinolytic system (D-dimer, tissue plasminogen activator antigen (tPA), urinary type plasminogen activator antigen (uPA), plasminogen activator inhibitor antigen (PAI-1)) and von Willebrand factor antigen (vWF) in 30 patients with sepsis or septic shock. All patients were treated with standard therapy, but 14 patients were treated additionally with an anti-TNF± monoclonal antibody (MAK 195F); 16 patients served as historical controls. No significant effect of the antibody on the parameters of the hemostatic system could be determined. Our data speak against a modulation of coagulation or the fibrinolytic system by the monoclonal anti-TNF± antibody MAK 195F in this cohort of sepsis patients.